Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians' Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669 for 2.0 Contact Hours.
This activity is supported by an educational grant/educational grant from AstraZeneca
Release Date: February 28, 2017
Expiration Date: February 28, 2018
Media: Internet - based
This activity features an expert presentation that illustrates approaches to choosing initial therapy for patients with advanced non–small cell lung cancers (NSCLCs) and mutations in the epidermal growth factor receptor (EGFR) gene, how to navigate the nuances regarding the evaluation of acquired resistance, newer approaches to molecular testing, choosing subsequent approaches to therapy, and managing patients with central nervous system metastases. The goal of this activity is to help physicians and nurses synthesize recent data sets on newly available and late-stage investigational strategies to manage their patients with EGFR-mutated, advanced NSCLCs and to place new evidence in its proper context for physicians and nurses engaged in the treatment/management of patients with these tumors.
Instructions for This Activity and Receiving Credit
This educational activity is directed toward medical oncologists who treat patients with lung cancers. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare professionals interested in the treatment of cancer are invited to participate.
At the conclusion of this activity, participants should be better prepared to:
Benjamin Levy, MD Associate Professor/Clinical Director, Medical Oncology
Johns Hopkins Medicine
Johns Hopkins Sidney Kimmel Cancer Center
Disclosure: Consultant: AstraZeneca, Celgene, Merck, Pfizer, Bristol-Myers Squibb, Eli Lilly, Genentech; Speakers Bureau: Genentech
It is the policy of PER® to ensure the fair balance, independence, objectivity, and scientific objectivity in all our CME activities. In accordance with ACCME guidelines, PER® requires everyone who is in a position to control the content of an educational activity, including spouses/partners, to disclose all relevant financial relationships with any commercial interest to participants as part of the activity planning process. PER® has implemented mechanisms to identify and resolve all conflicts of interest prior to release of this activity.
The staff of Physicians' Education Resource®, LLC, have no relevant financial relationships with commercial interests to disclose.
This CME/CE activity may or may not discuss investigational, unapproved, or off-label uses of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical and nursing education purposes only and is not meant to substitute for the independent clinical judgment of a physician or nurse relative to diagnostic, treatment, or management options for a specific patient’s medical condition.
The opinions expressed in the content are solely those of the individual faculty member and does not reflect those of PER® or any of the companies that provided commercial support for this activity.
Physicians’ Education Resource®, LLC
2 Clarke Drive
Cranbury, NJ 08512
Internet Explorer v.7 or greater (for Windows) | Mozilla Firefox v.2 or greater (for Windows, Mac, Linux)
Minimum System Requirements (Windows)
Minimum System Requirements (Mac OS)
ONS: PER Forum™: Nursing Opportunities to Improve Outcomes With the Advent of PARP Inhibitors in the Care of Women’s Cancers
May 17, 2018
ONS: Working Group for Changing Standards in EGFR-Mutated Lung Cancers: Real-World Applications of the Evidence for Nurses
May 17, 2018
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of Cancers
May 30, 2018
May 31, 2018
May 31, 2018